Condition: Pancreatic Cancer Resectable · Pancreatic Ductal Adenocarcinoma · Minimal Residual Disease · Sponsor: University Hospital, Montpellier
The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after 1. curative-intended surgery and 2. adjuvant chemotherapy. FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project
This description comes directly from the study's public registry record.
Catherine ALIX-PANABIERES, Ph.D · +33411759931 · c-panabieres@chu-montpellier.fr
Thomas BARDOL, M.D. · +33467339069 · t-bardol@chu-montpellier.fr
Always discuss trial participation with your own doctor first.
| CHU de Montpellier | Montpellier, Hérault, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06287749